Poly(amidoamine) Dendrimer/Camptothecin Complex: From Synthesis to In Vitro Cancer Cell Line Studies

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Mar 29

PMID 36985668

Authors

Ewa Oledzka

Klaudia Pasnik

Izabela Domanska

Monika Zielinska-Pisklak

Urszula Piotrowska

Marcin Sobczak

Lukasz Szeleszczuk

Anna Laskowska

Affiliations

Soon will be listed here.

Abstract

Camptothecin (CPT), an alkaloid with potent anticancer activity, is still not used in clinical practice due to its high hydrophobicity, toxicity, and poor active-form stability. To address these shortcomings, our research focuses on the encapsulation of this drug in the poly(amidoamine) (PAMAM) dendrimer macromolecule. The PAMAM dendrimer/CPT complex was synthesized and thoroughly characterized. The in vitro drug release study revealed that the drug was released in a slow and controlled manner in acidic and physiological conditions and that more than 80% of the drug was released after 168 h of incubation. Furthermore, it was demonstrated that CPT was released with first-order kinetics and non-Fickian transport. The studies on the hemolytic activity of the synthesized complex indicated that it is hemocompatible for potential intravenous administration at a concentration ≤ 5 µg/mL. Additionally, the developed product was shown to reduce the viability of non-small-cell lung cancer cells (A549) in a concentration- and time-dependent manner, and cancer cells were more susceptible to the complex than normal fibroblasts. Lastly, molecular modeling studies revealed that the lactone or carboxylic forms of CPT had a significant impact on the shape and stability of the complex and that its formation with the lactone form of CPT was more energetically favorable for each subsequent molecule than the carboxylic form. The report represents a systematic and structured approach to develop a PAMAM dendrimer/CPT complex that can be used as an effective drug delivery system (DDS) for the potential treatment of non-small-cell lung cancer.

Citing Articles

Future-Oriented Nanosystems Composed of Polyamidoamine Dendrimer and Biodegradable Polymers as an Anticancer Drug Carrier for Potential Targeted Treatment.

Strzelecka K, Kasinski A, Biela T, Bocho-Janiszewska A, Laskowska A, Szeleszczuk L Pharmaceutics. 2024; 16(11).

PMID: 39598604 PMC: 11597463. DOI: 10.3390/pharmaceutics16111482.

References

Sun H, Zhang J, Zhang Y, Yang L, Yuan L, Liu Y . Interaction of human serum albumin with 10-hydroxycamptothecin: spectroscopic and molecular modeling studies. Mol Biol Rep. 2011; 39(5):5115-23. DOI: 10.1007/s11033-011-1307-z. View

Reichert J, Wenger J . Development trends for new cancer therapeutics and vaccines. Drug Discov Today. 2008; 13(1-2):30-7. DOI: 10.1016/j.drudis.2007.09.003. View

Siepmann J, Gopferich A . Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev. 2001; 48(2-3):229-47. DOI: 10.1016/s0169-409x(01)00116-8. View

Liu Y, Bryantsev V, Diallo M, Goddard 3rd W . PAMAM dendrimers undergo pH responsive conformational changes without swelling. J Am Chem Soc. 2009; 131(8):2798-9. DOI: 10.1021/ja8100227. View

Mostovaya O, Shiabiev I, Pysin D, Stanavaya A, Abashkin V, Shcharbin D . PAMAM-Calix-Dendrimers: Second Generation Synthesis, Fluorescent Properties and Catecholamines Binding. Pharmaceutics. 2022; 14(12). PMC: 9781744. DOI: 10.3390/pharmaceutics14122748. View

Esfand R, Tomalia D . Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 2001; 6(8):427-436. DOI: 10.1016/s1359-6446(01)01757-3. View

Nguyen T, Nguyen B, Nguyen D, Nguyen N, Nguyen D, Khoa Nguyen C . Retrovirus Drugs-Loaded PEGylated PAMAM for Prolonging Drug Release and Enhancing Efficiency in HIV Treatment. Polymers (Basel). 2022; 14(1). PMC: 8747428. DOI: 10.3390/polym14010114. View

Thiagarajan G, Ray A, Malugin A, Ghandehari H . PAMAM-camptothecin conjugate inhibits proliferation and induces nuclear fragmentation in colorectal carcinoma cells. Pharm Res. 2010; 27(11):2307-16. PMC: 3092430. DOI: 10.1007/s11095-010-0179-6. View

Janaszewska A, Ciolkowski M, Wrobel D, Petersen J, Ficker M, Christensen J . Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups reveals negligible toxicity against three rodent cell-lines. Nanomedicine. 2013; 9(4):461-4. DOI: 10.1016/j.nano.2013.01.010. View

10.

Peng J, Zhou W, Xia X, Qi X, Sun L, Wang M . Encapsulation of acetylshikonin by polyamidoamine dendrimers for preparing prominent nanoparticles. AAPS PharmSciTech. 2014; 15(2):425-33. PMC: 3969479. DOI: 10.1208/s12249-014-0074-2. View

11.

Otto D, de Villiers M . All-atomistic molecular dynamics (AA-MD) studies and pharmacokinetic performance of PAMAM-dendrimer-furosemide delivery systems. Int J Pharm. 2018; 547(1-2):545-555. DOI: 10.1016/j.ijpharm.2018.06.033. View

12.

Dash S, Murthy P, Nath L, Chowdhury P . Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010; 67(3):217-23. View

13.

Parveen S, Sahoo S . Polymeric nanoparticles for cancer therapy. J Drug Target. 2008; 16(2):108-23. DOI: 10.1080/10611860701794353. View

14.

Kalomiraki M, Thermos K, Chaniotakis N . Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine. 2016; 11:1-12. PMC: 4694674. DOI: 10.2147/IJN.S93069. View

15.

Misra R, Acharya S, Sahoo S . Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today. 2010; 15(19-20):842-50. DOI: 10.1016/j.drudis.2010.08.006. View

16.

Gravel E, Bourget P, Mercier L, Paci A . Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives. J Pharm Biomed Anal. 2005; 39(3-4):581-6. DOI: 10.1016/j.jpba.2005.05.010. View

17.

Abedi-Gaballu F, Dehghan G, Ghaffari M, Yekta R, Abbaspour-Ravasjani S, Baradaran B . PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 2018; 12:177-190. PMC: 6269116. DOI: 10.1016/j.apmt.2018.05.002. View

18.

Sarkar K, Yang H . Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles. Drug Deliv. 2008; 15(5):343-6. DOI: 10.1080/10717540802035343. View

19.

Hobbs S, Monsky W, Yuan F, ROBERTS W, Griffith L, Torchilin V . Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998; 95(8):4607-12. PMC: 22537. DOI: 10.1073/pnas.95.8.4607. View

20.

Hatefi A, Amsden B . Camptothecin delivery methods. Pharm Res. 2002; 19(10):1389-99. DOI: 10.1023/a:1020427227285. View